After Final Amendment

A final office action (FOA) is a USPTO rejection that closes prosecution — after a final rejection, the applicant's options for responding are more limited than after a non-final rejection. The applicant must choose among: (1) AFTER-FINAL AMENDMENT — file an amendment under 37 C.F.R. § 1.116 within 3 months of the FOA (extendable by up to 3 months for large fee); the examiner MAY enter the amendment if it places the application in condition for allowance or doesn't raise new issues — but the examiner is not required to enter an after-final amendment; (2) AFCP 2.0 — After Final Consideration Pilot program: file a non-broadening amendment with a request for an interview; the examiner is allocated up to 3 hours to consider the amendment and hold an interview; no additional fee; (3) REQUEST FOR CONTINUED EXAMINATION (RCE) — reopens prosecution entirely; the RCE filing fee (~$900 small entity) automatically gives the applicant a new round of examination; however, RCE consumes Patent Term Adjustment under the C-delay rule; (4) APPEAL TO PTAB — file a Notice of Appeal within the statutory period; proceed to Board briefing and hearing; preserves PTA better than RCE; (5) ABANDONMENT — let the application go abandoned; retain ability to file a continuation if a parent application remains pending.

After Final Consideration Pilot 2.0 (AFCP 2.0) is a USPTO program that allows patent applicants to file a non-broadening claim amendment after a final rejection and request that the examiner conduct a limited consideration (up to 3 examiner hours) and hold an examiner interview. REQUIREMENTS: (1) NON-BROADENING — the amendment must not broaden any claim; it can only narrow claims or cancel claims; if any claim would be broadened by the amendment, AFCP 2.0 is not available; (2) NO ADDITIONAL FEE — AFCP 2.0 does not require any additional USPTO fee beyond what is normally required for an after-final response; (3) REQUEST MUST BE MADE — the applicant must specifically request AFCP 2.0 consideration in the after-final response; (4) EXAMINER DISCRETION — the examiner has up to 3 hours to consider the response and hold an interview; if the examiner concludes the amendment places the application in condition for allowance or raises a new issue, they can enter the amendment; if 3 hours are not enough or the amendment raises new issues, the examiner may decline to enter it and issue an advisory action. BENEFIT: AFCP 2.0 can result in allowance without an RCE or appeal, saving both time and PTA loss; the interview component is valuable — many after-final situations resolve through an examiner-applicant discussion that identifies a claim formulation acceptable to both parties. STRATEGIC USE: particularly useful when the applicant has a clear path to allowance by narrowing one specific limitation — the examiner can confirm allowance in the interview without formal office action.

An advisory action is a USPTO communication issued after the applicant files an after-final amendment that the examiner declines to enter or that does not place the application in condition for allowance. The advisory action: (1) Typically informs the applicant whether the amendment would be entered and, if not, why; (2) Notes whether the amendment would be entered in the event of an appeal (some after-final amendments are entered into the record for appeal purposes even if not for examination); (3) Confirms the period for reply and informs the applicant of their remaining options (RCE, appeal, abandon); (4) May summarize the examiner's reasons for maintaining the rejection. TIMING: the USPTO has no strict statutory deadline for issuing an advisory action after an after-final response, but typically does so within 2–3 months; the advisory action doesn't restart the period for reply — the applicant's 6-month deadline runs from the final office action date (or the advisory action date, whichever is later, up to statutory maximum). AFTER AN ADVISORY ACTION: the applicant may file an RCE (which is most common after an adverse advisory action); appeal; or abandon. The advisory action is not itself a new rejection — it's a procedural communication about the status of the after-final amendment and the maintenance of the final rejection.

Key deadlines after a final office action: (1) 2 MONTHS (extendable): the standard period for reply to a final office action — if no action is taken within 2 months of the mailing date, the application faces abandonment unless the period is extended; (2) EXTENSIONS: the 2-month period can be extended by 1, 2, or 3 months by paying extension fees (each month of extension costs progressively more; the maximum extension is 3 months, for a total of 5 months); (3) MAXIMUM 6 MONTHS: the absolute maximum reply period from the date of the final office action is 6 months — this is a statutory maximum under 35 U.S.C. § 133 and cannot be further extended; (4) APPEAL PERIOD: a Notice of Appeal to the PTAB must be filed within the period for reply (up to 6 months from the FOA); (5) AFCP 2.0: the applicant files the after-final amendment + AFCP request within the reply period (same 2-month base, extendable); (6) RCE DEADLINE: an RCE must be filed before the application is abandoned — within the 6-month maximum statutory period (or any shortened period from extensions already used); (7) ADVISORY ACTION TIMING: if an advisory action is issued after month 2 but before month 3, the period runs from the later of the advisory action date or 3 months from the final office action date.

Decision framework for post-final actions: FIGHT AFTER-FINAL (amendment + AFCP 2.0): Best when: the rejection is a close call that a narrowing amendment can overcome; you have a specific claim limitation that the examiner indicated would be acceptable in a prior interview; the amendment is clearly non-broadening; you want to preserve PTA (after-final amendments under AFCP 2.0 don't trigger C-delay like RCEs do). FILE AN RCE: Best when: after-final arguments or AFCP 2.0 failed or are unlikely to work; you need more substantive prosecution without the cost and time of an appeal; you need to maintain copendency for a continuation application; the application has moderate commercial value and PTA is not critical. APPEAL TO PTAB: Best when: the examiner's rejection is legally incorrect; prior RCEs haven't resolved the rejection; you need to preserve PTA for a high-value application (pharma/biotech); the issue is one of legal interpretation (claim construction, § 101, § 112) where PTAB can provide clearer guidance than an examiner. ABANDON: sometimes the right answer is letting a less-important application go and filing a fresh continuation with better claim language, especially if prosecution history estoppel concerns are mounting. The key metric is always: what is the expected value of the issued patent given the claim scope achievable? Balance that against the cost and PTA impact of each option.